arrow
A

Amy L. Dunn

Erasmus MC
H指数:28
被引数:2,663

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of recombinant von Willebrand factor in on-demand treatment of children with von Willebrand disease: up to 4 years of phase 3/3b follow-up

重组血管性血友病因子在血管性血友病患者儿童按需治疗中的有效性和安全性:长达4年的III/IIIb期随访

2026-08-010
PRE
National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population

国家出血性疾病基金会关于在遗传性出血性疾病人群中实验室筛查有无贫血的铁缺乏的临床实践建议

2026-03-090
OAAI
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025

《WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025》

2025-10-250
OAAI
Point-of-Care Musculoskeletal Ultrasound for Haemophilic Arthropathy: A Scoping Review of Scanning Protocols by the Imaging Expert Working Group of the International Prophylaxis Study Group

床旁肌肉骨骼超声在血友病性关节病中的应用:国际预防研究组影像专家工作组对扫描方案的概述性综述

2025-09-180
OAAI
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe haemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial

XTEND-Kids III期跨国试验中,接受每周一次efanesoctocog alfa预防治疗的<12岁重度血友病A患儿的出血事件事后分析及临床相关药代动力学参数。

2025-07-210
PRE
Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study

valoctocogene roxaparvovec联合预防性糖皮质激素的安全性及有效性:来自3b期、单臂、开放标签GENEr8-3研究的1年结果

2025-01-011
PRE
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors

使用epacog beta (rFVIIa) 进行出血治疗可使患有a型或b型血友病的成人和青少年患者的再出血发生率降低

2024-12-150
OA
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
2024-07-185
PRE
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
2024-07-0111
OAAI
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

在3期试验GENEr8-1中,valocologene roxaparvovec基因治疗严重血友病A后的健康相关生活质量

2023-12-0110
PRE
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
2023-02-23107
OA
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

使用抑制剂治疗和控制血友病A或B的儿科受试者 (<12岁) 出血的Eptacog beta功效和安全性

2022-04-279
OA